dc.contributor
Institut Català de la Salut
dc.contributor
[Ramos H] Grup de Recerca en Diabetis i Metabolisme, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ICSIII), Madrid, Spain. [Augustine J, Karan BM, Stitt AW, Curtis TM] Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry & Biomedical Science, Queen’s University Belfast, Belfast, Northern Ireland, UK. [Hernández C, Simó R] Grup de Recerca en Diabetis i Metabolisme, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ICSIII), Madrid, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Augustine, Josy
dc.contributor.author
Karan, Burak Mugdat
dc.contributor.author
Hernandez, Cristina
dc.contributor.author
Stitt, Alan
dc.contributor.author
Curtis, Tim
dc.contributor.author
Ramos Abellán, Hugo
dc.contributor.author
Simó Canonge, Rafael
dc.date.accessioned
2025-02-04T14:39:09Z
dc.date.available
2025-02-04T14:39:09Z
dc.date.issued
2025-01-16T12:30:34Z
dc.date.issued
2025-01-16T12:30:34Z
dc.date.issued
2024-11-30
dc.identifier
Ramos H, Augustine J, Karan BM, Hernández C, Stitt AW, Curtis TM, et al. Sitagliptin eye drops prevent the impairment of retinal neurovascular unit in the new Trpv2+/− rat model. J Neuroinflammation. 2024 Nov 30;21:312.
dc.identifier
https://hdl.handle.net/11351/12427
dc.identifier
10.1186/s12974-024-03283-5
dc.identifier
001367880600001
dc.identifier.uri
http://hdl.handle.net/11351/12427
dc.description.abstract
Diabetes; Diabetic retinopathy; Sitagliptin
dc.description.abstract
Diabetis; Retinopatia diabètica; Sitagliptina
dc.description.abstract
Diabetes; Retinopatía diabética; Sitagliptina
dc.description.abstract
Impaired function of the retinal neurovascular unit (NVU) is an early event in diabetic retinopathy (DR). It has been previously shown that topical delivery of the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin can protect against diabetes-mediated dysfunction of the retinal NVU in the db/db mouse. The aim of the present study was to examine whether sitagliptin could prevent the DR-like lesions within the NVU of the new non-diabetic model of DR, the Trpv2 knockout rat (Trpv2+/−). For that purpose, at 3 months of age, Trpv2+/− rats were topically treated twice daily for two weeks with sitagliptin or PBS-vehicle eyedrops. Trpv2+/+ rats treated with vehicle served as the control group. Body weight and glycemia were monitored. Optical coherence tomography recordings, fundus images and retinal samples were obtained to evaluate sitagliptin effects. The results revealed that sitagliptin eye drops had no effect on body weight or glycemia. Vehicle-treated Trpv2+/− rats exhibited retinal thinning and larger diameters of major retinal blood vessels, upregulation of inflammatory factors and oxidative markers, glial activation and formation of acellular capillaries. However, topical administration of sitagliptin significantly prevented all these abnormalities. In conclusion, sitagliptin eye drops exert a protective effect against DR-like lesions in Trpv2+/− rats. Our results suggest that sitagliptin eye drops carry significant potential to treat not only early-stages of DR but also other diseases with impairment of the NVU unrelated to diabetes.
dc.description.abstract
We are grateful to EAsDEC skills award program, Belfast Association for the Blind, MICIN (PID2022-138544OB-I00), ISCIII (ICI20/00129), Biotechnology and Biological Sciences Research Council (BB/I026359/1) and Diabetes UK (18/0005791) for funding this work.
dc.format
application/pdf
dc.relation
Journal of Neuroinflammation;21
dc.relation
https://doi.org/10.1186/s12974-024-03283-5
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Retinopatia diabètica - Tractament
dc.subject
Enzims proteolítics - Inhibidors - Ús terapèutic
dc.subject
Solucions (Farmàcia)
dc.subject
Rates (Animals de laboratori)
dc.subject
Tomografia de coherència òptica
dc.subject
DISEASES::Eye Diseases::Retinal Diseases::Diabetic Retinopathy
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
ORGANISMS::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Eutheria::Rodentia::Muridae::Murinae::Rats
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protease Inhibitors
dc.subject
Other subheadings::Other subheadings::/therapeutic use
dc.subject
CHEMICALS AND DRUGS::Pharmaceutical Preparations::Solutions::Pharmaceutical Solutions::Ophthalmic Solutions
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Optical Imaging::Tomography, Optical::Tomography, Optical Coherence
dc.subject
ENFERMEDADES::oftalmopatías::enfermedades de la retina::retinopatía diabética
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
ORGANISMOS::Eukaryota::animales::Chordata::vertebrados::mamíferos::Eutheria::Rodentia::Muridae::Murinae::ratas
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteasas
dc.subject
Otros calificadores::Otros calificadores::/uso terapéutico
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::preparados farmacéuticos::soluciones::soluciones farmacéuticas::soluciones oftálmicas
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::imágenes ópticas::tomografía óptica::tomografía de coherencia óptica
dc.title
Sitagliptin eye drops prevent the impairment of retinal neurovascular unit in the new Trpv2+/− rat model
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
